noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5
Peakequity Partners Management Co LLC

Thoma Bravo Completes Strategic Investment in PeakEquity Portfolio[...]
Peakequity Partners Management Co LLC

HighLevel Announces Minority Growth Investment from General Atlantic

Healthcare

Pappas Capital LLC

09/23/2024 | Press release | Archived content

BioAtla and Context Therapeutics Announce Exclusive Worldwide Lic...

News | 09. 23. 2024

BioAtla

SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 -- BioAtla, Inc. ("BioAtla") (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ("CAB") antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. ("Context") (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE. Context will assume and fund all development and commercialization activities.

Pappas Capital LLC published this content on September 23, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format